NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT01139450,Study of 0417 Ointment in the Treatment of Atopic Dermatitis,https://clinicaltrials.gov/study/NCT01139450,,COMPLETED,"The aim of this trial is to assess the efficacy of 0417 Ointment in the Treatment of Atopic Dermatitis.

Treatment medication will be administered as follows: Apply a thin layer of ointment to affected skin areas twice daily and rub in gently and completely. Study medication will be applied twice a day, approximately 12 hours apart, for approximately 4 weeks.",YES,Atopic Dermatitis,DRUG: 0417|DRUG: Vehicle of 0417 test product|DRUG: Tacrolimus Ointment 0.03%,"Incidence of Success Based on the Investigator's Global Evaluation at the End of Treatment, 4 weeks","The Mean Change From Baseline in the Total Individual Clinical Signs and Symptoms Per Body Region, Baseline, 4 weeks|The Mean Change From Baseline in Pruritus, Baseline, 4 weeks|The Mean Change From Baseline in the Percentage Total Body Surface Affected (%BSA), Baseline, 4 weeks",,Fougera Pharmaceuticals Inc.,,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE3,899,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",0417,2008-01,2009-08,2009-08,2010-06-08,2014-09-23,2014-10-09,"Fougera Pharmaceuticals Inc., Melville, New York, 11747, United States",
